EBElodie Bournique

Elodie Bournique

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elodie Bournique has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PARP1 trapping activates ATM-mediated NF-κB signaling independent of replication in response to TOP1 blockade

    by Elodie Bournique, Ambrocio Sanchez, Kim Ha, Katrina M Yan, Lavanya Manjunath, Gisselle Santiago, Pedro Ortega, Rémi Buisson

    The NF-κB signaling pathway is a key driver of inflammation and can be activated by many genotoxic stresses. Yet, the mechanisms by which different types of DNA damage trigger NF-κB remain poorly understood. In this study, we find that NF-κB activation by topoisomerase 1 (TOP1) inhibition is strongly increased when cells are treated in combination with PARP inhibitors. Mechanistically, we demonstrate that TOP1 inhibition activates ATM-mediated NF-κB signaling through two distinct pathways: a replication-dependent pathway triggered by replication fork collapse and a replication-independent pathway revealed upon PARP1 inhibition. We further show that PARP1 enzymatic activity is not required to suppress NF-κB signaling after TOP1 inhibition during the replication-independent pathway. Instead, PARP inhibitors trap PARP1 at DNA lesions, thereby blocking repair and promoting ATM-dependent NF-κB signaling, mimicking the cell response to TDP1 depletion. These findings reveal an unexpected role for PARP1 as an NF-κB activator when trapped at DNA lesions induced by TOP1 inhibition, providing a therapeutic opportunity to use PARP inhibitors to enhance inflammatory responses and potentially improve the efficacy of TOP1-targeted cancer therapies.


  • Nouveaux mécanismes de réponse cellulaire au stress réplicatif : rôles des ADN polymérases spécialisées êta et thêta

    by Elodie Bournique

    La réplication de l'ADN permet la duplication fidèle du génome avant la transmission d'une copie identique à chaque cellule-fille. Ce mécanisme complexe met en jeu de nombreuses protéines et est finement régulé afin de limiter au maximum le nombre d'erreurs (ou mutations), qui peuvent compromettre l'homéostasie cellulaire à l'origine de certaines pathologies telles que le cancer. La structure de l'ADN peut être modifiée par des agents exogènes de type radiations ou molécules chimiques mais également par les différentes voies métaboliques intrinsèques à la cellule (respiration, transcription...) ou par des changements de la conformation tridimensionnelle induits par la séquence d'acides nucléiques elle-même. L'ensemble de ces altérations représente des obstacles pour le bon déroulement de la réplication de l'ADN, appelés "stress réplicatif", pouvant aboutir à la formation de cassures de l'ADN, sources majeures d'instabilité chromosomique. Il a été montré que le stress réplicatif est un évènement précoce dans le développement tumoral. Il permet aux cellules en cours de transformation d'acquérir l'instabilité génétique nécessaire à leur prolifération incontrôlée et, une fois la tumeur formée, à la résistance aux traitements anti-tumoraux. Cependant, une instabilité génétique trop importante et non maitrisée est également le talon d'Achille des tumeurs, puisque le chaos génétique n'est plus compatible avec leur survie. Ainsi, dans les cellules tumorales, des mécanismes d'adaptation aux stress réplicatif, potentiellement différents des cellules normales, sont alors mis en place. Au cours de ma thèse, j'ai mis en évidence deux mécanismes d'adaptation au stress de la réplication, développés par les cellules tumorales, qui mettent en jeux des ADN polymérases spécialisées. Dans une première partie, je démontre le rôle de l'ADN polymérase spécialisée êta (Pol êta) dans la réplication et dans le maintien des télomères des cellules tumorales. Dans un premier temps, j'ai confirmé par différentes techniques la présence de Pol êta au niveau des télomères. Puis, j'ai montré que la perte de Pol êta est à l'origine d'un retard de réplication au niveau des télomères, compensé par une synthèse d'ADN aux télomères en mitose. Dans les cellules utilisant le mécanisme de maintien des télomères ALT (basé sur la recombinaison homologue), la perte de cette polymérase augmente l'instabilité des télomères et l'activité du mécanisme ALT. Dans une seconde partie, je mets en évidence la capacité des cellules tumorales à signaler à la génération suivante la perturbation de la réplication induite par un agent exogène. Ceci permet aux cellules-filles de modifier leur programme de réplication, et notamment d'avancer le moment de leur réplication au cours de la phase S pour anticiper ce stress et donc en diminuer les conséquences sur la stabilité du génome. J'ai également étudié le rôle de l'ADN polymérase spécialisée thêta et de la protéine Rif1 dans ce processus d'adaptation, car ces deux protéines sont connues pour être impliquées à la fois dans la régulation du programme de réplication, et dans la réparation des cassures de l'ADN.

  • Open Access

    Mechanism of DNA replication fork breakage and PARP1 hyperactivation during replication catastrophe

    by Pedro Ortega, Elodie Bournique, Junyi Li, Ambrocio Sanchez, Gisselle Santiago, Brooke R. Harris, Josefine Striepen, John Maciejowski, Abby M. Green, Rémi Buisson

    Ataxia telangiectasia and Rad3-related (ATR) inhibition triggers a surge in origin firing, resulting in increased levels of single-stranded DNA (ssDNA) that rapidly deplete all available RPA. This leaves ssDNA unprotected and susceptible to breakage, a phenomenon known as replication catastrophe. However, the mechanism by which unprotected ssDNA breaks remains unclear. Here, we reveal that APOBEC3B is the key enzyme targeting unprotected ssDNA at replication forks, initiating a reaction cascade that induces fork collapse and poly(ADP-ribose) polymerase 1 (PARP1) hyperactivation. Mechanistically, we demonstrate that uracils generated by APOBEC3B at replication forks are removed by UNG2, resulting in abasic sites that are subsequently cleaved by APE1 endonuclease. Moreover, we show that APE1-mediated DNA cleavage is the critical enzymatic step for PARP1 hyperactivation in cells, regardless of how abasic sites are generated on DNA. Last, we demonstrate that APOBEC3B-induced PARP1 trapping and DNA double-strand breaks drive cell sensitivity to ATR inhibition, creating a context of synthetic lethality when coupled with PARP inhibitors.


  • Open Access

    Cooperative role of PACT and ADAR1 in preventing aberrant PKR activation by self-derived double-stranded RNA

    by Lavanya Manjunath, Gisselle Santiago, Pedro Ortega, Ambrocio Sanchez, Sunwoo Oh, Alexander Garcia, Junyi Li, Dana Duong, Elodie Bournique, Alexis Bouin, et al.

    Double-stranded RNAs (dsRNAs) produced during viral infections are recognized by the innate immune sensor protein kinase R (PKR), triggering a host translation shutoff that inhibits viral replication and propagation. Given the harmful effects of uncontrolled PKR activation, cells must tightly regulate PKR to ensure that its activation occurs only in response to viral infections, not endogenous dsRNAs. Here, we use CRISPR-Translate, a FACS-based genome-wide CRISPR-Cas9 knockout screening method that exploits translation levels as a readout and identifies PACT as a key inhibitor of PKR during viral infection. We find that PACT-deficient cells hyperactivate PKR in response to different RNA viruses, raising the question of why cells need to limit PKR activity. Our results demonstrate that PACT cooperates with ADAR1 to suppress PKR activation from self-dsRNAs in uninfected cells. The simultaneous deletion of PACT and ADAR1 results in synthetic lethality, which can be fully rescued in PKR-deficient cells. We propose that both PACT and ADAR1 act as essential barriers against PKR, creating a threshold of tolerable levels to endogenous dsRNA in cells without activating PKR-mediated translation shutdown and cell death.


  • Open Access

    Cooperative Role of PACT and ADAR1 in Preventing Aberrant PKR Activation by Self-Derived Double-Stranded RNA

    by Lavanya Manjunath, Gisselle Santiago, Pedro Ortega, Ambrocio Sanchez, Sunwoo Oh, Alexander Garcia, Elodie Bournique, Alexis Bouin, Bert L. Semler, Dheva Setiaputra, et al.

    Double-stranded RNAs (dsRNAs) produced during viral infections are recognized by the innate immune sensor protein kinase R (PKR), triggering a host translation shutoff that inhibits viral replication and propagation. Given the harmful effects of uncontrolled PKR activation, cells must tightly regulate PKR to ensure that its activation occurs only in response to viral infections, not endogenous dsRNAs. Here, we use CRISPR-Translate, a FACS-based genome-wide CRISPR-Cas9 knockout screening method that exploits translation levels as a readout and identifies PACT as a key inhibitor of PKR during viral infection. We find that cells deficient for PACT hyperactivate PKR in response to several different RNA viruses, raising the question of why cells need to limit PKR activity. Our results demonstrate that PACT cooperates with ADAR1 to suppress PKR activation from self-dsRNAs in uninfected cells. The simultaneous deletion of PACT and ADAR1 results in synthetic lethality, which can be fully rescued in PKR-deficient cells. We propose that both PACT and ADAR1 act as essential barriers against PKR, creating a threshold of tolerable levels to endogenous dsRNA in cells without activating PKR-mediated translation shutdown and cell death.


  • Open Access

    ATR safeguards replication forks against APOBEC3B-induced toxic PARP1 trapping

    by Pedro Ortega, Elodie Bournique Bournique, Junyi Li, Ambrocio Sanchez, Gisselle Santiago, Brooke R. Harris, Abby Margaret Green, Rémi Buisson

    ATR is the master safeguard of genomic integrity during DNA replication. Acute inhibition of ATR with ATR inhibitor (ATRi) triggers a surge in origin firing, leading to increased levels of single-stranded DNA (ssDNA) that rapidly deplete all available RPA. This leaves ssDNA unprotected and susceptible to breakage, a phenomenon known as replication catastrophe. However, the mechanism by which unprotected ssDNA breaks remains unclear. Here, we reveal that APOBEC3B is the key enzyme targeting unprotected ssDNA at replication forks, triggering a reaction cascade that induces fork collapse and PARP1 hyperactivation. Mechanistically, we demonstrate that uracils generated by APOBEC3B at replication forks are removed by UNG2, creating abasic sites that are subsequently cleaved by APE1 endonuclease. Moreover, we demonstrate that APE1-mediated DNA cleavage is the critical enzymatic step for PARP1 trapping and hyperactivation in cells, regardless of how abasic sites are generated on DNA. Finally, we show that APOBEC3B-induced toxic PARP1 trapping in response to ATRi drives cell sensitivity to ATR inhibition, creating to a context of synthetic lethality when combined with PARP inhibitors. Together, these findings reveal the mechanisms that cause replication forks to break during replication catastrophe and explain why ATRi-treated cells are particularly sensitive to PARP inhibitors.


  • Open Access

    Pyrimidine Triones as Potential Activators of p53 Mutants

    by Maryam M. Jebril Fallatah, Özlem Demir, Fiona Law, Linda Lauinger, Roberta Baronio, Linda Hall, Elodie Bournique, Ambuj Srivastava, Landon Tyler Metzen, Zane Norman, et al.

    P53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.


  • Top Cited Papers
    Open Access

    Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes

    by Ambrocio Sanchez, Pedro Ortega, Ramin Sakhtemani, Lavanya Manjunath, Sunwoo Oh, Elodie Bournique, Alexandrea Becker, Kyumin Kim, Cameron Durfee, Nuri Alpay Temiz, et al.

    Antiviral DNA cytosine deaminases APOBEC3A and APOBEC3B are major sources of mutations in cancer by catalyzing cytosine-to-uracil deamination. APOBEC3A preferentially targets single-stranded DNAs, with a noted affinity for DNA regions that adopt stem-loop secondary structures. However, the detailed substrate preferences of APOBEC3A and APOBEC3B have not been fully established, and the specific influence of the DNA sequence on APOBEC3A and APOBEC3B deaminase activity remains to be investigated. Here, we find that APOBEC3B also selectively targets DNA stem-loop structures, and they are distinct from those subjected to deamination by APOBEC3A. We develop Oligo-seq, an in vitro sequencing-based method to identify specific sequence contexts promoting APOBEC3A and APOBEC3B activity. Through this approach, we demonstrate that APOBEC3A and APOBEC3B deaminase activity is strongly regulated by specific sequences surrounding the targeted cytosine. Moreover, we identify the structural features of APOBEC3B and APOBEC3A responsible for their substrate preferences. Importantly, we determine that APOBEC3B-induced mutations in hairpin-forming sequences within tumor genomes differ from the DNA stem-loop sequences mutated by APOBEC3A. Together, our study provides evidence that APOBEC3A and APOBEC3B can generate distinct mutation landscapes in cancer genomes, driven by their unique substrate selectivity.


  • Open Access

    Mesoscale DNA Features Impact APOBEC3A and APOBEC3B Deaminase Activity and Shape Tumor Mutational Landscapes

    by Ambrocio Sanchez, Pedro Ortega, Ramin Sakhtemani, Lavanya Manjunath, Sunwoo Oh, Elodie Bournique, Alexandrea Becker, Kyumin Kim, Cameron Durfee, Nuri Alpay Temiz, et al.

    Antiviral DNA cytosine deaminases APOBEC3A and APOBEC3B are major sources of mutations in cancer by catalyzing cytosine-to-uracil deamination. APOBEC3A preferentially targets singlestranded DNAs, with a noted affinity for DNA regions that adopt stem-loop secondary structures. However, the detailed substrate preferences of APOBEC3A and APOBEC3B have been fully established, and the specific influence of the DNA sequence on APOBEC3A APOBEC3B deaminase activity remains to be investigated. Here, we find that APOBEC3B selectively targets DNA stem-loop structures, and they are distinct from those subjected deamination by APOBEC3A. We develop Oligo-seq, a novel in vitro sequencing-based to identify specific sequence contexts promoting APOBEC3A and APOBEC3B activity. Through this approach, we demonstrate that APOBEC3A an APOBEC3B deaminase activity is strongly regulated by specific sequences surrounding the targeted cytosine. Moreover, we identify structural features of APOBEC3B and APOBEC3A responsible for their substrate preferences. Importantly, we determine that APOBEC3B-induced mutations in hairpin-forming sequences within tumor genomes differ from the DNA stem-loop sequences mutated by APOBEC3A. Together, our study provides evidence that APOBEC3A and APOBEC3B can generate mutation landscapes in cancer genomes, driven by their unique substrate selectivity.


  • Open Access

    Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage

    by Chloe Wick, Seyed Arad Moghadasi, Jordan T. Becker, Elisa Fanunza, Sunwoo Oh, Elodie Bournique, Rémi Buisson, Reuben S. Harris